PhuturdexDrug Pipeline Intelligence

Phuturdex › Diseases › Lysosomal storage disease

Drugs in development · updated 30 October 2026

Lysosomal storage disease: drugs in development

As of 30 October 2026 there are 12 active clinical trials (recruiting or ongoing, phases I–III) on 11 drugs for lysosomal storage disease. 11 are experimental, that is not yet approved in the United States.

12Active trials
11Experimental drugs
3Experimental, in phase III

Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.

Sign in free →

Experimental drugs

Not yet approved by the US FDA for any indication.

DrugMost advanced phaseActive trialsReference trial
GNR-055II–III1NCT05208281
OTL-200III1NCT04283227
RGX-121II–III1NCT03566043
4D-310I–II2NCT05629559
AB-1009I–II1NCT07282847
DFT383I–II1NCT06910813
FBX-101I–II1NCT05739643
PBGM01I–II1NCT04713475
PLX-200II1NCT07740512
RP-A501II1NCT06092034
SPK-3006I–II1NCT04093349

Sorted by most advanced phase and number of active trials.

All 11 drugs, with the details

In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.

Open in Phuturdex →

Specific forms

Broader categories

Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D016464 “Lysosomal Storage Diseases”.

ItalianoFrançaisDeutsch